Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06144788
PHASE2

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

Sponsor: Jeil Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients with Type 2 Diabetes Mellitus

Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients With Type 2 Diabetes Mellitus

Key Details

Gender

All

Age Range

19 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

161

Start Date

2023-11-03

Completion Date

2024-12-23

Last Updated

2026-07-07

Healthy Volunteers

No

Interventions

DRUG

SGLT2 inhibitor

SGLT 1/2 dual inhibitor

Locations (1)

Severance Hospital

Seoul, Seodaemun-gu, South Korea